The Filing Desk

Accendra Health

ACH · NYSE · Health Care · Financials, fiscal 2016 to 2025

ACH · Last close · November 16, 2026
$0.09
Value Accendra Health yourself

Accendra Health's revenue rose 3.1% to $2.8 billion in fiscal 2025. Its operating margin was 1.0%, up from −8.1% a year earlier. Free cash flow was −$293 million. It paid out $10 million in dividends and buybacks. The diluted share count rose 0.2%.

Accendra Health, Inc. Latest fiscal year ended December 31, 2025 10-K filed February 20, 2026 · 0001104659-26-018169 Updated
Revenue
$2.8B
3.1%
Operating margin
1.0%
9.1 pts
Net income
−$1.1B
 
Free cash flow
−$293M
 
Return on capital
1.2%
7.8 pts
Market cap
$7M
Nov 16 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

About these figures. Return on equity for fiscal 2025 is blank: the 10-K's structured data doesn't include every figure it needs.

Charts show fiscal years, from the 10-K filings.

What Accendra Health does

Accendra Health, formerly Owens & Minor, provides home healthcare equipment, supplies and services in the U.S. Its two brands are Apria and Byram Healthcare. It serves people with diabetes, breathing conditions (including home oxygen and ventilation) and sleep apnea, and supplies ostomy, wound care, urology and incontinence products.

It earns revenue through fee-for-service and capitation arrangements with large government and commercial payors (the insurers and programs that pay for care) for equipment, supplies and services rented and sold to patients. Most items are prescribed by a physician as part of a care plan.

On December 31, 2025, it completed the sale of its Products & Healthcare Services business for an aggregate of $375 million in cash, subject to adjustments, and kept a 5% equity interest in it.

Its biggest risks, as it describes them

  • Depending heavily on a few payors, including the recent end of its contracts with a large commercial payor.
  • A Medicare decision that could reduce reimbursement for non-invasive ventilation products.
  • Losing its relationships with hospital and physician referral sources.
  • Relying on certain significant suppliers.
  • Risks from the sale of its Products & Healthcare Services business.
From Accendra Health's annual report on Form 10-K, filed February 20, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

From fiscal 2016 to 2022, earnings per share fell 26.0% a year and net income 23.2% a year, as new shares raised the share count by 25% and diluted each share's earnings. Accendra Health then lost money in fiscal 2023, 2024 and 2025.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments567024328282
Debt incl. finance leases—2,5012,0981,8412,050
Net debt (negative means net cash)—2,4311,8541,8141,768
Net debt to EBITDA—6.5x5.4x—7.3x
Debt to equity—2.6x2.2x3.1x—
Interest coverage7.7x1.1x1.1x−2.0x0.3x
Current ratio1.7x1.5x1.1x1.1x0.6x
Quick ratio0.6x0.6x0.5x1.1x0.5x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Accendra Health's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

What Accendra Health says to expect

  • Full year 2026: net revenue and adjusted EBITDAThe Company expects that full year net revenue will be at the bottom end of the prior outlook range of $2.45 billion to $2.55 billion and that adjusted EBITDA could be as much as 30% lower than the $310 million midpoint of the prior outlook range.
The company's own words, from its earnings release (Form 8-K, Exhibit 99), filed November 5, 2026. They are its expectations, not ours, and not a forecast or price target from The Filing Desk. Replaced when the next release is out.

Insider trades

Over the 12 months between November 20, 2025 and November 19, 2026, no insider bought Accendra Health shares on the open market, and 1 insider sold $4,046, all of it under trading plans set up in advance.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Nov 16, 2026Perry A BernocchiOtherSold plan33,161$0.12$4,046Form 4
Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score4 of 95 of 92 of 9
Rule of 40−52.1%4.7%−7.5%
Altman Z''0.920.09−2.59
Accruals ratio−14.9%−10.8%−28.1%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positivePassPassFail
Return on assets roseFailFailFail
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assetsPassPassFail
Current ratio roseFailFailFail
Share count didn't riseFailPassFail
Gross margin rosePassFailFail
Revenue rose relative to assetsFailPassPass
F-score4 of 95 of 92 of 9
Companies that report no gross profit are scored on the other eight.

Compare

Put Accendra Health side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Accendra HealthFY253.1%1.0%−10.6%1.2%7.3x2
111FY25−12.8%−0.0%0.9%———Compare
Henry ScheinFY254.0%5.0%4.3%7.5%3.1x6Compare
MedlineFY2511.5%7.8%4.6%—3.3x—Compare
Cosmos HealthFY2519.9%−25.6%−13.0%−53.0%—5Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue9,7239,3189,4189,2118,4809,7859,9562,5532,6802,762
Revenue growth−0.5%−4.2%1.1%−2.2%−7.9%15.4%1.7%−74.4%5.0%3.1%
Gross profit1,1871,1721,0701,1281,2811,5131,8262,1252,2191,289
Research and development—————12121313—
Operating income20089−35273204368143133−21828
Net income10973−437−623022222−41−363−1,101
Diluted EPS (US$)1.761.20−7.28−1.030.472.940.29−0.53−4.73−14.31
Diluted shares (millions)61606061647676777777
Cash flow
Cash from operations18857116166339124325741162−102
Capital expenditure203545425041158172170191
Free cash flow167227112428983167568−9−293
Dividends paid6363485110000
Share buybacks715000000010
Acquisitions03677520001,6850018
Stock-based compensation12121616202521141713
Balance sheet at fiscal year end
Cash and short-term investments186104666783567024328282
Debt incl. finance leases5699171,6771,5721,037—2,5012,0981,8412,050
Total assets2,7183,3763,7743,6433,3363,5375,3865,0934,6562,452
Total liabilities1,7582,3613,2553,1812,6242,5984,4414,1694,0702,913
Shareholders' equity9601,016518462712938967945586−461
Margins and ratios
Gross margin12.2%12.6%11.4%12.2%15.1%15.5%18.4%83.3%82.8%46.7%
Operating margin2.0%1.0%−3.7%0.8%2.4%3.8%1.4%5.2%−8.1%1.0%
Net margin1.1%0.8%−4.6%−0.7%0.3%2.3%0.2%−1.6%−13.5%−39.9%
Free cash flow margin1.7%0.2%0.8%1.3%3.4%0.8%1.7%22.3%−0.3%−10.6%
Rule of 40 (growth + FCF margin)1.2%−3.9%1.8%−0.9%−4.5%16.2%3.4%−52.1%4.7%−7.5%
Return on capital9.2%5.6%−14.1%2.8%9.0%——2.5%−6.6%1.2%
Return on equity11.1%7.4%−57.0%−12.7%5.1%26.9%2.4%−4.3%−47.4%—
Return on assets4.0%2.4%−12.2%−1.7%0.9%6.5%0.5%−0.8%−7.4%−31.0%
Net debt to EBITDA1.5x5.5x—7.9x3.2x—6.5x5.4x—7.3x
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Accendra Health's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Accendra Health.